33.3 C
Vientiane
Wednesday, May 14, 2025
spot_img
Home Blog Page 657

Sikhai-Sikeuth Highway Upgrade to Complete by March End

Sikhai-Sikeuth Highway Upgrade to Complete by March End
Sikhai-Sikeuth Highway Upgrade to Complete by March End

The paving of the northern section of National Road 13’s 6.3-kilometer Sikhai-Sikeuth highway in Vientiane is nearing completion and is expected to be finished by the end of March, according to Dalavieng Chanthalangsy, Project Manager for the highway upgrade.

This section stretches between Sikhottabong and Naxaithong districts. 

Currently, crews are laying concrete between the Sikhai and Dongnathong junctions, Dalavieng noted on 12 February. The remaining work—including curbs, footpaths, and lane markings—is on schedule to be completed by 31 March, in line with the original plan.

Sikhai-Sikeuth Highway Upgrade Project
Sikhai-Sikeuth Highway Upgrade Project

As part of the broader improvements, sections of National Road 13 are also being widened and resurfaced with concrete, including a 58-kilometer stretch between Sikeuth village and Phonhong district’s National Road 13 (North). The upgrade will expand the road from two to four lanes, with a two-meter-wide median strip, motorcycle lanes on both sides, and 1.5-meter-wide sidewalks.

The USD 10.29 million project also includes streetlights, closed drainage ditches, and other infrastructure enhancements. It is part of the ongoing improvements to northern National Road 13, a vital route connecting China to Cambodia through Laos.

Tangchaleun Group Co., Ltd. is leading the construction in collaboration with Dongsung, Dasan Consulting (South Korea), and Lao Consulting Group. The project has an 18-month construction period, followed by a three-year maintenance phase. Funding is provided by the World Bank, the Asian Infrastructure Investment Bank, the Nordic Development Fund, and the Lao government.

Weibo Corporation to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

BEIJING, Feb. 17, 2025 /PRNewswire/ — Weibo Corporation (Nasdaq: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the fourth quarter and fiscal year 2024 before the U.S. market opens on Thursday, March 13, 2025. Following the announcement, Weibo’s management team will host a conference call from 7 AM8 AM Eastern Time on March 13, 2025 (or 7 PM8 PM Beijing Time on March 13, 2025) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link: https://register.vevent.com/register/BIf3e83e2236a24ff5839823fdb84a4a1f

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:
Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com

Boldyn Networks appoints Sara Dickinson as Group CFO

The executive brings significant experience in critical finance roles at sizeable companies

LONDON, Feb. 17, 2025 /PRNewswire/ — Boldyn Networks (Boldyn), one of the world’s largest shared network infrastructure providers, announced the appointment of Sara Dickinson as Group Chief Financial Officer (CFO). Sara brings significant experience in critical finance roles across both public and private sectors. She joins Boldyn from BSI, where she served as Group CFO for the past three years.

Sara Dickinson, Boldyn Networks Group CFO
Sara Dickinson, Boldyn Networks Group CFO

At BSI, a global services company operating in over 60 countries, Sara led a significant transformation of the business and operating model. Prior to BSI, she spent five years at Expedia Group in senior finance roles, including SVP Finance and CFO for the B2B division, where she guided the business through a high-growth phase. Her extensive experience includes senior executive roles at Costa Coffee and Sage plc, further demonstrating her capability in leading financial strategies and operations.

Igor Leprince, Boldyn Networks Group CEO said: “I am delighted to welcome Sara to our executive team during this exciting phase for our business. She is not only a proven CFO with extensive experience in complex international businesses with digital and technological components, but she also excels in guiding companies through growth, transformation, and acquisitions. Sara’s expertise in leading change is invaluable. Furthermore, she aligns perfectly with our culture and values at Boldyn.”

“I’d like to extend my heartfelt thanks to Stephen Matthews for his close to 12 incredible years of financial leadership, which have been pivotal in Boldyn’s integration, growth and success. As Stephen returns home to Australia, he will play a crucial role in onboarding Sara to her new position, where she will oversee our Group Finance and Legal functions”, he continued.

“I’m very excited to join Boldyn Networks and support the company’s unstoppable growth, driven by its strong values”, said Sara Dickinson, Group CFO at Boldyn Networks. “Boldyn is a game changer in the technology industry and is disrupting many sectors with shared connectivity that’s sustainable and cost efficient. I’m thrilled to be part of this journey.”

 

Japan Festival Celebrates 70th Anniversary of Japan-Laos Diplomatic Relations

Japan Ambassader and Lao government took a picture with the Shishimai (Japanese lion dance) by Takafuji Ukon

Thousands of locals, residents and visitors have been treated to the sights, sounds and tastes of Japan at the 2025 Japan Festival in Vientiane Capital on 14-15 February

Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

SHANGHAI, Feb. 17, 2025 /PRNewswire/ — Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness.

Fosun Pharma's Layout in AI Field
Fosun Pharma’s Layout in AI Field

Self-developed PharmAID Decision Intelligence Platform Integrates Global Leading Large Model Technology and Has connected with Deepseek R1

As a pioneer in the AI transformation of the pharmaceutical industry, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform internally. This platform establishes a full lifecycle intelligent decision-making network covering innovative R&D scenarios. Deeply integrated with global leading large model technologies, the platform has taken the lead in connecting to with Deepseek R1. Based on the PharmAID decision intelligence platform, Fosun Pharma is accelerating the development of “drug commercial value-assisted decision-making” capabilities, broadening decision-making perspectives, and improving decision accuracy. The platform enhances drug R&D efficiency and accelerates the transformation of R&D achievements by integrating point prediction, conformational prediction, binding mechanism analysis, toxicology optimization, medical writing, and clinical information extraction. This initiative aims to lead innovation and transformation, and it is the first self-developed AI decision intelligence platform in pharmaceutical industry.

The PharmAID decision intelligence platform offers AI translation and AI medical writing/revision features, significantly improving information retrieval and writing efficiency under the support of AI technology. At present, the PharmAID decision intelligence platform has integrated multiple professional clinical information and pipeline data platforms around the world, increasing content generation accuracy in the pharmaceutical and healthcare field by 50% compared to general large models, with data updated at T+1, ensuring outstanding accuracy and timeliness. Moreover, Fosun Pharma applies AI technology to carry out intelligent training for sales personnel and further assists business scenarios, achieving “more precise” marketing. Through the deep empowerment of the PharmAID decision intelligence platform, Fosun Pharma is building its digital competitiveness, leading the entire pharmaceutical industry into a new era of AI-driven innovation.

AI Technology Empowers Innovative R&D and Accelerate Breakthroughs

Fosun Pharma actively promotes AI-driven innovation. As early as 2022, Fosun Pharma formed a strategic partnership with AI pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug R&D, aiming to integrate AI with physical modeling to jointly advance new drug development processes. This collaboration leverages DP Technology’s technical strength and project experience in the “AI for Science” field, combining expertise in drug discovery and AI computing to provide new insights for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets.

Building an “AI+X” Smart Healthcare Ecosystem

In medical devices sector, Fosun Aitrox, a subsidiary of Fosun Pharma, focuses on the medical AI field and is one of the few companies in China offering comprehensive AI medical service solutions across multiple departments including radiology, pathology, ultrasound, cardiology, respiratory, orthopedics, neurology, and thyroid and breast surgery. Fosun Aitrox delves into medical institutions and primary healthcare service scenarios, identifying real needs and enhancing service capabilities in core scenarios of tiered healthcare systems, including early screening, remote diagnosis, and precision medicine. Through the “AI+X” model, Fosun Aitrox collaborates deeply with top medical centers, promoting the transformation of scientific research achievements and the popularization of standardized medical systems, empowering the construction of smart diagnosis and treatment systems. Its three major AI-assisted diagnostic product lines—radiology imaging, pathology imaging, and ultrasound imaging—have been widely used clinically and have won multiple world championships in international competitions.

Fosun Aitrox’s AI medical imaging products can quickly and accurately analyze medical imaging data, providing doctors with diagnostic suggestions, helping them more efficiently identify lesions and assess conditions, thereby improving diagnostic accuracy and timeliness. The application of this technology not only enhances the quality and efficiency of medical services but also benefits patients in remote and resource-scarce areas, allowing them to access high-quality medical services locally. To date, Fosun Aitrox has expanded its presence to cover 70% of China, with operating businesses in over 20 provinces, establishing nearly 10 regional smart healthcare project models. The company has released and is developing more than 70 AI products.

Additionally, Fosun Pharma’s incubated company, JeDiCare, leverages its extensive experience in image navigation algorithm development and interventional consumable design, along with a global perspective, to innovatively introduce AR navigation technology into minimally invasive surgery. Its self-developed puncture surgery navigation device (AR navigation puncture positioning system) is currently under market application review. This product features proprietary “monocular vision augmented reality” technology, integrating computer vision monocular tracking and AR display technology, not only achieving precise positioning but also optimizing the positioning process. In the future, with the assistance of the AR navigation puncture positioning system, primary hospitals will also be able to perform precise thoracoscopic surgeries, bringing high-quality medical care to more patients.

Looking ahead, Fosun Pharma will continue to increase investment and exploration in AI, accelerating the construction of AI innovation across the entire industry chain through independent research and external collaborations, leading the AI transformation of the pharmaceutical industry, and contributing more wisdom and strength to the cause of human health.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit our official website: www.fosunpharma.com

 

 

Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

SHANGHAI, Feb. 17, 2025 /PRNewswire/ — Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness.

Fosun Pharma's Layout in AI Field
Fosun Pharma’s Layout in AI Field

Self-developed PharmAID Decision Intelligence Platform Integrates Global Leading Large Model Technology and Has connected with Deepseek R1

As a pioneer in the AI transformation of the pharmaceutical industry, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform internally. This platform establishes a full lifecycle intelligent decision-making network covering innovative R&D scenarios. Deeply integrated with global leading large model technologies, the platform has taken the lead in connecting to with Deepseek R1. Based on the PharmAID decision intelligence platform, Fosun Pharma is accelerating the development of “drug commercial value-assisted decision-making” capabilities, broadening decision-making perspectives, and improving decision accuracy. The platform enhances drug R&D efficiency and accelerates the transformation of R&D achievements by integrating point prediction, conformational prediction, binding mechanism analysis, toxicology optimization, medical writing, and clinical information extraction. This initiative aims to lead innovation and transformation, and it is the first self-developed AI decision intelligence platform in pharmaceutical industry.

The PharmAID decision intelligence platform offers AI translation and AI medical writing/revision features, significantly improving information retrieval and writing efficiency under the support of AI technology. At present, the PharmAID decision intelligence platform has integrated multiple professional clinical information and pipeline data platforms around the world, increasing content generation accuracy in the pharmaceutical and healthcare field by 50% compared to general large models, with data updated at T+1, ensuring outstanding accuracy and timeliness. Moreover, Fosun Pharma applies AI technology to carry out intelligent training for sales personnel and further assists business scenarios, achieving “more precise” marketing. Through the deep empowerment of the PharmAID decision intelligence platform, Fosun Pharma is building its digital competitiveness, leading the entire pharmaceutical industry into a new era of AI-driven innovation.

AI Technology Empowers Innovative R&D and Accelerate Breakthroughs

Fosun Pharma actively promotes AI-driven innovation. As early as 2022, Fosun Pharma formed a strategic partnership with AI pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug R&D, aiming to integrate AI with physical modeling to jointly advance new drug development processes. This collaboration leverages DP Technology’s technical strength and project experience in the “AI for Science” field, combining expertise in drug discovery and AI computing to provide new insights for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets.

Building an “AI+X” Smart Healthcare Ecosystem

In medical devices sector, Fosun Aitrox, a subsidiary of Fosun Pharma, focuses on the medical AI field and is one of the few companies in China offering comprehensive AI medical service solutions across multiple departments including radiology, pathology, ultrasound, cardiology, respiratory, orthopedics, neurology, and thyroid and breast surgery. Fosun Aitrox delves into medical institutions and primary healthcare service scenarios, identifying real needs and enhancing service capabilities in core scenarios of tiered healthcare systems, including early screening, remote diagnosis, and precision medicine. Through the “AI+X” model, Fosun Aitrox collaborates deeply with top medical centers, promoting the transformation of scientific research achievements and the popularization of standardized medical systems, empowering the construction of smart diagnosis and treatment systems. Its three major AI-assisted diagnostic product lines—radiology imaging, pathology imaging, and ultrasound imaging—have been widely used clinically and have won multiple world championships in international competitions.

Fosun Aitrox’s AI medical imaging products can quickly and accurately analyze medical imaging data, providing doctors with diagnostic suggestions, helping them more efficiently identify lesions and assess conditions, thereby improving diagnostic accuracy and timeliness. The application of this technology not only enhances the quality and efficiency of medical services but also benefits patients in remote and resource-scarce areas, allowing them to access high-quality medical services locally. To date, Fosun Aitrox has expanded its presence to cover 70% of China, with operating businesses in over 20 provinces, establishing nearly 10 regional smart healthcare project models. The company has released and is developing more than 70 AI products.

Additionally, Fosun Pharma’s incubated company, JeDiCare, leverages its extensive experience in image navigation algorithm development and interventional consumable design, along with a global perspective, to innovatively introduce AR navigation technology into minimally invasive surgery. Its self-developed puncture surgery navigation device (AR navigation puncture positioning system) is currently under market application review. This product features proprietary “monocular vision augmented reality” technology, integrating computer vision monocular tracking and AR display technology, not only achieving precise positioning but also optimizing the positioning process. In the future, with the assistance of the AR navigation puncture positioning system, primary hospitals will also be able to perform precise thoracoscopic surgeries, bringing high-quality medical care to more patients.

Looking ahead, Fosun Pharma will continue to increase investment and exploration in AI, accelerating the construction of AI innovation across the entire industry chain through independent research and external collaborations, leading the AI transformation of the pharmaceutical industry, and contributing more wisdom and strength to the cause of human health.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of “Innovation for Good Health”, continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation.

For more information, please visit our official website: www.fosunpharma.com

 

Per Franzén appointed new CEO of EQT AB as of May 2025

  • The Board of Directors of EQT AB (“EQT”) has appointed Per Franzén as new CEO and Managing Partner, effective as of the Annual Shareholders’ Meeting on 27 May 2025. During this transition period, Christian Sinding will remain as CEO.
  • Per Franzén has spent nearly two decades at EQT, currently serving as Deputy Managing Partner and Head of Private Capital Europe & North America. He has been instrumental to EQT’s growth and success, most recently leading the EUR 22 billion raise of EQT X, which was the largest private equity fund closed globally in 2024.
  • After the transition, Christian Sinding will become an Institutional Partner. In this role he will Chair the EQT Council, which brings together some of EQT’s most experienced leaders with external expertise to build partnerships and provide EQT and its clients the insights needed to stay ahead in an ever-evolving world. He will also continue to Chair the Global Investment Forum and remain a member of several Investment Committees.

STOCKHOLM, Feb. 17, 2025 /PRNewswire/ — The Board of Directors of EQT AB (“EQT”) has appointed Per Franzén as the new CEO and Managing Partner of EQT, effective as of the Annual Shareholders’ Meeting on 27 May 2025. Per Franzén will succeed Christian Sinding, who has led EQT through a period of extraordinary transformation, growing the firm from a market capitalization of around EUR 7 billion at the time of its 2019 IPO to around EUR 40 billion at the time of this announcement. Per becomes CEO at a time of strength for EQT, which recently reported record levels of investments, increased exit activity, and significant portfolio valuation growth for 2024. This transition sets EQT up for continued success as it enters a EUR 100 billion fundraising cycle and looks to execute on new initiatives, including launching additional investment strategies, expanding distribution channels, and accelerating brand building efforts.

Per has spent nearly two decades at EQT, currently serving as Head of Private Capital Europe & North America and Deputy Managing Partner. He has been instrumental to EQT’s success, most recently leading the EUR 22 billion raise of EQT X, which was the largest private equity fund closed globally in 2024. Today, EQT Private Capital Europe & North America manages EUR 113 billion in total assets under management, making it EQT’s largest business line.

Commenting on his appointment, Per Franzén, said: “It is an honor to be appointed CEO of EQT. I am truly passionate about the firm, having spent most of my career here, and I am deeply committed to building on the fantastic global platform we have established under Christian’s leadership. It’s exciting to lead EQT into its next chapter together with the team and the support of the Board, and I’m grateful that Christian will remain at EQT as an Institutional Partner. I look forward to continuing to deliver exceptional value to our clients and shareholders, while upholding our core values.”

Christian Sinding will remain CEO during the period leading up to the Annual Shareholders’ Meeting, to ensure the best possible transition. Christian, who joined EQT in 1998 and has served as CEO since 2019, will then become an Institutional Partner. In this role he will Chair the newly formed EQT Council, which aims to amplify EQT’s ability to create meaningful partnerships, provide clients with the insights needed to succeed for the long-term, and accelerate the impact of its global business. Christian will also continue to Chair the Global Investment Forum, which brings together EQT’s most senior investment professionals to optimize performance by sharing expertise and insights from across all of EQT’s strategies. He will remain a member of several EQT fund Investment Committees.

“As I reflect on my journey with EQT so far, I am filled with immense pride and gratitude for what we have accomplished together as a firm. Going from being employee number eleven to having nearly two thousand fantastic colleagues in over twenty markets is an unforgettable journey. Together, we have shown that a values-driven firm, which attracts and retains exceptional people, can deliver excellent performance that in the process benefits both our clients and the world at large,” said Christian Sinding, incoming Institutional Partner at EQT. “I would like to thank Conni and the rest of the Board for their support during my time as CEO. I am proud to hand over the leadership to Per and as Chair of the Council and Global Investment Forum, as well as through my membership of several investment committees, I am excited to continue supporting EQT.”

Conni Jonsson, Chairperson of the Board of EQT, said: “Christian has taken EQT through a period of remarkable transformation. His vision, dedication and unwavering commitment have been instrumental in establishing EQT’s leading global position. He successfully led us through our 2019 IPO and has had a relentless attention to performance and culture as EQT has expanded into new markets and strategies. On behalf of the Board, I would like to extend my deepest appreciation to Christian and I am pleased that he will become an Institutional Partner.”

“This is the next logical step for EQT and we now enter an exciting new phase with Per at the helm. I have worked with Per for nearly two decades, so I know he is a role model for EQT’s distinct values and performance-driven culture. As Head of EQT Private Capital Europe & North America, Per has proven his ability to build and lead a large, multi-strategy, international team. I look forward to supporting him on this next step and am confident that with Per as CEO, thanks to his experience and performance mindset, EQT will continue delivering outstanding results for our clients and shareholders,” added Conni Jonsson.

This is information that EQT AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on 17 February 2025.

About Per Franzén

Per Franzén joined EQT Partners in Stockholm in May 2007. He currently serves as Head of Private Capital Europe and North America and Deputy Managing Partner. He is a member of the EQT Executive Committee and Chairman of the Equity Partners Investment Committee.

Per is currently based in London but has previously worked in the Stockholm and Munich offices. He has been involved in a number of investments, including Anticimex, IVC Evidensia and IFS. Prior to joining EQT, Per spent six years at Morgan Stanley’s London and Stockholm offices working in M&A, Leveraged Finance and Nordic Banking.

Please find photos of Per Franzén here.

About the EQT Council

The EQT Council aims to amplify EQT’s ability to create meaningful partnerships, provide clients the insights needed to succeed for the long-term, and accelerate the impact of its global business. The EQT Council brings together some of EQT’s most experienced leaders with external expertise and is Chaired by Christian Sinding. 

From EQT, members also include EQT AB Chairperson Conni Jonsson and Lennart Blecher, Head of Real Assets and Deputy Managing Partner. They are joined by Marcus Wallenberg, the Vice Chair of Investor AB who holds a number of other Director and Board roles. Over time, EQT plans to expand the Council to further strengthen its expertise.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/eqt/r/per-franzen-appointed-new-ceo-of-eqt-ab-as-of-may-2025,c4106371

The following files are available for download:

https://mb.cision.com/Main/87/4106371/3267837.pdf

PR_Per Franzén appointed new CEO of EQT AB_17.02.25

https://news.cision.com/eqt/i/per-franzen-eqt,c3377893

Per Franzén_EQT

 

ANGEL J2810 Microfiltration Water Purifier Receives NSF Certification, Boosting Global Expansion

BANGKOK, Feb. 17, 2025 /PRNewswire/ — ANGEL, a global leader in water purification technology, announced that its J2810 series of microfiltration water filters has earned National Sanitation Foundation (NSF) certification after passing rigorous testing. All four products in the series meet the NSF/ANSI 42 standards for material safety and structural integrity. The certification, granted by the industry’s most trusted authority, is another recognition of ANGEL’s superior product quality, further strengthening its position for global expansion.

NSF certification is one of the most stringent standards in the global drinking water treatment industry, covering key testing dimensions including material safety, structural integrity, filtration effectiveness, and water quality improvement capabilities. Recognized by governments and enterprises worldwide, it is the most trusted certification in the water purification industry. The NSF-certified J2810 series microfiltration water filters underscore ANGEL’s technological innovation capabilities in the water purification industry and affirms the product’s readiness for international markets.

ANGEL Receives NSF Certification
ANGEL Receives NSF Certification

The J2810 series is a durable water filters designed specifically for the catering industry. Featuring high-efficiency microfiltration technology, it effectively removes particles, rust, sediment, and other impurities from water. The solution ensures safer and healthier water for the food service industry. The J2810 series includes parallel carbon fiber filters, quick-change filter design, and high compatibility, supporting both wall-mounted and floor-standing installations. It can be widely used in restaurants, cafes, milk tea shops, and fast food chains to meet the needs of various commercial settings, providing filtered water for ice machines, coffee machines, water boilers, soda machines, and other water-using equipment.

ANGEL's Commercial Kitchen Water Purification Solutions
ANGEL’s Commercial Kitchen Water Purification Solutions

Aiming to strengthen the company’s footprint in the commercial kitchen water filtration sector, ANGEL’s ultrafiltration and reverse osmosis water purifiers for food service industry are also undergoing NSF certification testing. ANGEL has made continuous breakthroughs in water purification technology and energy-saving solutions, releasing innovative water purification products that have earned recognition in domestic and international markets.

As global consumers become increasingly concerned about safe and healthy drinking water, the market demand for water purification solutions is surging rapidly. At this backdrop, ANGEL’s NSF certification demonstrates its top-tier product quality, and enhances the competitiveness in the global market. ANGEL will persist in driving technological innovation and advancing its global expansion, harnessing its expertise to provide superior, efficient, and intelligent water purification solutions for consumers worldwide.